Why CG Oncology, Inc. (CGON) stock rose 13.9% on Monday, November 16, 2026
CG Oncology, Inc. (CGON) closed at $84.78, up 13.95% on Monday, November 16, 2026, on volume of 9,851,612 shares (9.9× its 3-month average); market value about $7.60B, according to Nexqual market data (nexqual.com/moves/2026-11-16/CGON).
What happened: primary sources
Events Nexqual found for CGON on Monday, November 16, 2026 or the trading day before (November 13, 2026), each linked to its primary source:
- Nov 16, 2026: SEC 8-K: Other material event source
Quoted from the filing: “On November 16, 2026, the Company announced topline data for its Phase 3 PIVOT-006 registrational trial evaluating adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta 3 cm non-muscle invasive bladder cancer (" NMIBC ") following complete tumor resection. There are currently no U.S. Food and Drug Administration (" FDA ") approved adjuvant treatment options in this population of approximately 50,000 patients. PIVOT-006 achieved its primary endpoint, demonstrating statistically…”
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on CGON
CGON stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 16, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 18, 2026 at 20:48 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt